fatty acid Report issue

Small molecule Experimental
AACT PubChem

Active Ingredient History

NOW
  • Now
In biochemistry and nutrition, a polyunsaturated fat is a fat that contains a polyunsaturated fatty acid, which is a subclass of fatty acid characterized by a backbone with two or more carbon–carbon double bonds. Some polyunsaturated fatty acids are essentials. Polyunsaturated fatty acids are precursors to and are derived from polyunsaturated fats, which include drying oils.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

dha-enriched omega-3 polyunsaturated fatty acid | epa-enriched omega-3 polyunsaturated fatty acid | essential fatty acids | fatty acid | hyper-oxigenated fatty acid | long-chain fatty acids | medium chain fatty acid | medium-chain fatty acid | medium-chain fatty acids | medium-chain saturated fatty acids | middle-chain fatty acids | n-3 pufa | polyunsaturated fatty acid | polyunsaturated fatty acids | reesterified long-chain n-3 polyunsaturated fatty acids | unsaturated fatty acids

Organizations (83)

Research & Development (83)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (41)

Approved Indications (1)


 

Malnutrition

Experimental Indications - Clinical Trial Phases 1-4 (40)


 

Adenomatous Polyposis Coli (Phase 3)

Alcoholism (Phase 3)

alpha-Linolenic Acid (Phase 3)

Anti-Inflammatory Agents (Phase 3)

Atrial Fibrillation (Phase 3)

Attention Deficit and Disruptive Behavior Disorders (Phase 3)

Blepharitis (Phase 4)

Carcinoma, Hepatocellular (Phase 2/Phase 3)

Cardiomyopathy, Dilated (Phase 3)

Cardiovascular Diseases (Phase 3)

Child Development (Phase 2)

Conjunctivitis (Phase 2)

Critical Illness (Phase 4)

Docosahexaenoic Acids (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 1/Phase 2)

Dry Eye Syndromes (Phase 4)

Eicosapentaenoic Acid (Phase 3)

Fatty Acids (Phase 3)

Fatty Liver (Phase 2)

Fibrosis (Phase 2/Phase 3)

Health Behavior (Phase 2)

Heart Failure (Phase 3)

Hypertriglyceridemia (Phase 4)

Inflammation (Phase 2)

Liver Cirrhosis (Phase 2/Phase 3)

Liver Neoplasms (Phase 4)

Maternal Exposure (Phase 2)

Multiple Sclerosis (Phase 1/Phase 2)

Nutritional and Metabolic Diseases ()

Obesity (Phase 3)

Obesity, Morbid (Phase 2)

Pancreatic Neoplasms (Phase 4)

Parenteral Nutrition (Phase 3)

Pressure Ulcer (Phase 4)

Preventive Health Services (Phase 3)

Preventive Medicine (Phase 3)

Prostatic Neoplasms (Phase 1/Phase 2)

SARS-CoV-2 (Phase 3)

Schizophrenia (Phase 4)

Stomach Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 55
  • # of Trial Organizations: 83

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue